2022, Number 1
Next >>
Rev Med UAS 2022; 12 (1)
Neurofibromatosis Type 2: Genetic Syndrome of Predisposal to Cancer
Beltrán-Ontiveros S, Moreno-Ortiz J
Language: Spanish
References: 5
Page: 3-4
PDF size: 37.42 Kb.
Text Extraction
No abstract.
REFERENCES
Campian J, Gutmann DH. CNS Tumors in Neurofibromatosis. J Clin Oncol. 2017;35(21):2378-2385.doi:10.1200/JCO.2016.71.7199
Strowd RE 3rd, Plotkin SR. Familial Nervous System Tumor Syndromes [published correction appears inContinuum (Minneap Minn). 2021 Jun 1;27(3):801]. Continuum (Minneap Minn). 2020;26(6):1523-1552.doi:10.1212/CON.0000000000000950
Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. An update on the CNS manifestations of neurofibromatosistype 2 [published correction appears in Acta Neuropathol. 2019 Aug 20;:]. Acta Neuropathol.2020;139(4):643-665. doi:10.1007/s00401-019-02029-5
Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Druker H, et al. Cancer and Central NervousSystem Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. Clin CancerRes. 2017; 23(12):e54–e61. doi:10.1158/1078-0432.CCR-17-0590
Farschtschi S, Mautner VF, McLean ACL, Schulz A, Friedrich RE, Rosahl SK. The Neurofibromatoses.Dtsch Arztebl Int. 2020;117(20):354-360. doi:10.3238/arztebl.2020.0354
Full text